1,858 results on '"Bates, Susan"'
Search Results
52. Supplementary Figure 3 from Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway
53. Data from Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway
54. Supplementary Figure 2 from Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway
55. Supplementary Figure 1 from Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway
56. Supplementary Data from R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin
57. Supplementary Figure Legends from Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway
58. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
59. The ABCG2 Multidrug Transporter
60. Sew much love.
61. Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis
62. Extracellular Protein Kinase a as a Cancer Biomarker: Its Expression by Tumor Cells and Reversal by a Myristate-Lacking Cα and RIIβ Subunit Overexpression
63. King Solomon and the Baby: Children's Health in Early Childhood
64. A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat
65. Revisiting the role of ABC transporters in multidrug-resistant cancer
66. Projected changes in tropical cyclone activity under future warming scenarios using a high-resolution climate model
67. Supplemental Tables from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel
68. Supplementary Figure 4 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel
69. Supplementary Figure 5 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel
70. Supplementary Figure 3 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel
71. Supplementary Figure S1 from Impact of ABCB1 Allelic Variants on QTc Interval Prolongation
72. Supplementary Tables from Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers
73. Data from A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma
74. Supplementary Data from A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
75. Data from Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers
76. Supplementary Figure 1 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel
77. Supplementary Figure 8 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel
78. Supplementary Figure 2 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel
79. Supplementary Figure 1 from Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers
80. Data from Impact of ABCB1 Allelic Variants on QTc Interval Prolongation
81. Supplementary Data from A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine
82. Supplementary Figures S1-S6 from Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy
83. Supplementary Tables 1-3 from A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent
84. Supplementary Table 1 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
85. Supplementary Methods from Impact of ABCB1 Allelic Variants on QTc Interval Prolongation
86. Supplementary Results from Impact of ABCB1 Allelic Variants on QTc Interval Prolongation
87. Supplementary Figures from Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors
88. Supplementary Figure Legends from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel
89. Supplementary Figure 6 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel
90. Supplementary Figure 2 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
91. Supplementary Figure 3 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
92. Supplementary Tables and Figure from A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent
93. Supplementary Data from Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2
94. Supplementary Figure Legends 1-3 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
95. Data from A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine
96. Supplementary Data from A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma
97. Supplementary Figures S1-S4 from Evidence for Microtubule Target Engagement in Tumors of Patients Receiving Ixabepilone
98. Supplementary Figure 1 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
99. Supplementary Figure 7 from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel
100. Data from Histone Deacetylase Inhibitors Influence Chemotherapy Transport by Modulating Expression and Trafficking of a Common Polymorphic Variant of the ABCG2 Efflux Transporter
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.